First approved for adults in 2022, the therapy is now cleared for adults and pediatric patients weighing 66 lbs or more with symptomatic obstructive hypertrophic cardiomyopathy.
News|Articles|May 19, 2003
Vital Care puts pharmacies into home infusion business
Vital Care home care franchisers.
Advertisement
Advertisement
Related to this article
The once daily tablet is expected to reach US patients in October 2026.
The label expansion adds patients 12 years of age and older to the once daily alopecia areata indication.
Advertisement
Advertisement
Trending on Drug Topics
1
Serotype 34 Causes Pneumococcal Meningitis in Child With Cochlear Implants
2
Addressing Medication Adherence in Cardiometabolic Health
3
Retatrutide Delivers 20.8% Weight Loss in Adults With Type 2 Diabetes
4
From Binder to Action: Making Infectious Disease Outbreak Plans Operational
5